We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Test Significantly Reduces Mortality Associated With Staphylococcus aureus

By HospiMedica staff writers
Posted on 22 May 2007
Clinical data have demonstrated significantly reduced mortality and hospital costs associated with staphylococcal bloodstream infections (BSIs) due to a new nucleic acid test.

The 2.5-hour fluorescence in-situ hybridization (FISH) assay uses fluorescence-labeled peptide nucleic acid (PNA) probes that target the species-specific ribosomal RNA (rRNA) in bacteria and yeast. More...
PNA FISH is a qualitative nucleic acid hybridization assay intended for identification of organisms from blood cultures. Results are visualized using fluorescence microscopy. Fluorescing cells indicate the target species, while no fluorescence indicates another species is present in the positive blood culture.

A group of infectious disease specialists, headed by Shmuel Shoham M.D. presented data from a study of AdvanDx, Inc.'s (Woburn, MA, USA) PNA FISH diagnostic test at the 2007 annual scientific Meeting of the Society for Healthcare Epidemiology of America. The study took place at the Washington Hospital Center (DC, USA), which is the largest hospital in the nation's capital and among the 25 largest hospitals in the United States.

During the study, 202 patients whose blood culture tested positive for Gram-positive cocci (indicating a staphylococcal bloodstream infection) were alternately assigned to a control, or intervention, group. In the intervention group, PNA FISH results and general organism information were relayed to the treating clinician via a call from a hospital liaison, whereas control group patients did not receive a call with PNA FISH results.

According to the study, reporting of PNA FISH results led to an 80% reduction in intensive care unit (ICU)-related mortality due to S aureus BSIs; median hospital cost-savings of US$19,441 per patient; and a 61% reduction in patients receiving antibiotics for coagulase-negative staphylococci (CNS), which is often a blood culture contaminant that leads to unnecessary antibiotic therapy even though the patient does not have a true bloodstream infection.

"Rapid delivery of PNA FISH data from the laboratory to clinicians was associated with reduced mortality in ICU [intensive care unit] patients,” said Dr. Shoham, section of infectious diseases, director, transplant infectious diseases, Washington Hospital Center. There was also a trend toward reduced length of hospitalization in non-ICU patients with S aureus, and in patients with blood cultures growing CNS [coagulase-negative staphylococci], regardless of location within the hospital. AdvanDx, Inc.'s PNA FISH diagnostic tests provide rapid results that enable us to optimize antimicrobial therapy, improve patient outcomes, and reduce hospital costs,” added Dr. Shoham.


Related Links:
AdvanDx, Inc.
Washington Hospital Center

Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Vessel Sealing Instrument
ERGOseal
Hybrid Arch Device
Neo EDE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Critical Care

view channel
Image Credit: Adobe Stock

New ECG Foundation Model Enables Broad Cardiac Diagnosis and Risk Prediction

Electrocardiograms are central to cardiovascular decision-making, but conventional artificial intelligence models are often trained for narrow tasks, such as detecting a single arrhythmia.... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.